Novo plans Wegovy home delivery for eligible insured patients

Novo Nordisk is expanding a pharmacy pathway that previously served self-pay patients. The company is also adding an app and four wellness partners.

Author
HDM Staff
Save
Share

    LAS VEGAS — Novo Nordisk said Tuesday it plans to extend Wegovy home delivery to eligible patients with commercial or government insurance, including people who qualify for the Medicare GLP-1 Bridge. The expansion, expected to roll out in the coming weeks, would let some patients fill prescriptions through the same manufacturer-backed pharmacy as their payment circumstances change. Novo announced the plan alongside a redesigned Novocare website and a new app for people considering or taking its obesity medicine.

    The change addresses a problem that obesity medicine physician Alexandra Sowa described in a Main Stage conversation at HLTH USA. A patient can start with commercial coverage, move to self-pay after losing it and later qualify for Medicare. Each transition can send a practice back through the pharmacy routing process and give the patient another place to lose access to treatment. Sowa, founder and CEO of SoWell Health, led the discussion with Ed Cinca, Novo’s senior vice president of marketing and patient solutions.

    One place to send the prescription

    Cinca described the relaunch as a “one stop shop platform” for patients and healthcare professionals. His account of the planned pharmacy workflow was the most consequential part of the announcement for practices. Novo wants clinicians to be able to send prescriptions to Novocare Pharmacy for eligible insured patients as well as patients paying cash, with help determining which payment options are available. The company’s launch announcement put the insured home-delivery expansion in the coming weeks. It described the free membership website and app as part of the relaunch.

    Sowa called the existing process a source of “multiple points of contact where a patient could lose care and access.” From the practice’s side, a change in benefits can mean confirming which pharmacy can fill the order and which requirements apply before a patient gets the next supply. A single pharmacy destination could reduce some of that rerouting for people the service can fill for. Whether it will do so depends on how many patients are eligible, how quickly the new payment routes become available and what happens when an order cannot be filled through the program.

    Novo’s previous pharmacy materials already described home delivery and shipment updates for self-pay patients. The expansion builds on that channel. It also runs alongside retail and telehealth pathways, which Cinca said Novo would continue to support. For clinicians, the relevant comparison is how well each available pharmacy handles a particular prescription, given the patient’s coverage, price and delivery preferences.

    Coverage still depends on the payer

    Novo describes the redesigned service as a place to look up coverage and costs and get help by phone or live chat. Its coverage tool says its assessment does not guarantee coverage or the copay amount. Checking a plan’s rules can tell the office what it may have to do next, such as prepare a prior authorization. For a patient deciding where to send an order, the material question is what the pharmacy confirms at checkout.

    The federal option Cinca discussed is the Medicare GLP-1 Bridge, a CMS demonstration scheduled to run from July 1, 2026, through December 31, 2027. CMS says eligible beneficiaries enrolled in Part D can obtain certain GLP-1 drugs for weight management through the bridge with a $50 monthly copayment. The demonstration operates outside the standard Part D payment process. Its clinical and enrollment requirements still apply when a prescription goes through a manufacturer-backed pharmacy.

    The program’s rollout creates a distinction between accepting a prescription and getting medicine to the patient. A practice evaluating the new approach would want to know who can see an order’s status, how a denial or missing document is communicated and where a prescription goes if the chosen route cannot fill it. Those details determine whether a simpler front door removes work for a clinician or shifts follow-up to a different person in the office.

    Support after the prescription

    Sowa described a second problem that can arise after the first fill. In her practice, she said, “the support you need on day one is different than month three.” She described patients working through changes in eating, activity and day-to-day life over time. One example concerned a patient who felt unexpectedly distressed when trying on clothes after substantial weight loss. The story illustrated why a visit that focuses on weight or dosing alone can miss some of the changes the patient is trying to manage.

    The relaunch includes treatment information, progress tracking and access to third-party services. Cinca named dietitian provider Berry Street, meal-delivery company Factor, wearable company WHOOP and personal styling company Stitch Fix. The four offer distinct services, and Novo says their eligibility and costs can vary. Cinca said members would be able to “earn Novacare points throughout their journey.” The company said it expects its points program, which eligible members could use toward selected partner offers, by year-end.

    Clinicians will have separate questions about the tracking app and the pharmacy. One concerns whether the patient can see and understand the status of the next fill. Another concerns what patients can do with information they record between visits, including whether a concern makes it back to the team responsible for their treatment when it matters. Novo described features and partnerships in the session. It did not present comparative results showing whether the redesigned program reduces delays, keeps patients in treatment longer or changes clinical outcomes.

    For Novo, the relaunch extends its relationship with patients past checkout and into services they may use after treatment begins. For practices, the more immediate test comes when a patient’s payment source changes or a refill is due and there is a problem. If the expanded channel gives both the practice and patient a clear answer about what the order needs next, it could address the specific gap Sowa described. The planned insurance rollout will determine which patients can use it.

    The expansion also gives practices a concrete way to judge the rollout. They can compare the time from prescription to first fill for patients using the new channel and track how often staff have to redirect an order. Neither measure was included in Tuesday’s announcement.

    Photo: Ed Cinca and Alexandra Sowa discuss Novocare on the Main Stage. Credit: HLTH USA 2026.